Psychedelic and nutraceutical brand Cybin Corp. and drug delivery company IntelGenx have partnered to develop oral dissolving film for psilocybin consumption.
Why Does It Matter?
Cybin Chief Executive Officer Paul Glavine says "orally-dissolving psilocybin film" bypasses the digestive system and provides "faster-acting relief for individuals with anxiety disorders who require more immediate symptom relief."
Chief Medical Officer Jukka Karjalainen noted that orally-dissolving psilocybin expects to produce higher bioavailability levels than pills. The doctor added that the film would have a fraction of the dosage required in a capsule.
"Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner," Karjalainen said.
The agreement marks the latest bit of activity for the psychedelics company.
Last week, the company announced it entered into a reverse takeover agreement with mining issuer Clarmin Explorations Inc. (TSX.V: CX).
Related links:
Cybin Partners With Toronto Centre For Psychedelic Science For Psilocybin Research Project
'Psyched': Military Invests $27M In Psychedelic Research, Atai Launches DTx Platform, Psilocybin Decriminalization Rejected In Iowa
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Top Cannabis Event In New Jersey
Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!